Loading...
Patients with chronic obstructive pulmonary disease (COPD) often do not receive β-blockers because of concerns that they might exacerbate respiratory symptoms. Using Danish registries from 1995 to 2015, investigators studied the incidence of COPD hospitalizations among 300,000 new users of β-blockers and among 1 million new users of other antihypertensive agents; patients with histories of COPD were excluded.
Compared with patients who received other antihypertensive agents, patients who received β-blockers had significantly lower adjusted risks for COPD hospitalization (6.5 vs. 9.2 cases/1000 person-years; adjusted hazard ratio, 0.8) and all-cause mortality (1.8 vs. 3.1 deaths/1000 person-years; aHR, 0.6). Outcomes remained robust in variou…